Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 54 for “"Ticagrelor"”.
-
Defining the molecular pharmacology of ticagrelor
… activation (constitutive activity). Ticagrelor, a widely used therapeutic platelet inhibitor that blocks ADP-dependent P2Y₁₂ receptor stimulation, was recently shown to act as an inverse agonist at the P2Y₁₂ receptor, reducing its basal constitutive activity. Interestingly, although …
-
Desenvolvimento de método analítico para avaliação de impurezas orgânicas de ticagrelor
O ticagrelor é um novo fármaco destinado para a prevenção de síndromes coronarianas agudas (SCA) caracterizadas pela formação de placas ateroscleróticas que se rompem no interior das artérias. Atua de forma diferenciada na inibição da ação plaquetária, inibindo de forma reversível e não competitiva …
-
The pharmacodynamics of the antiplatelet drug ticagrelor: mode of action, onset and reversibility.
… Of the currently available antiplatelet agents, ticagrelor has been shown to be superior both in clinical trials and laboratory studies. However, much debate exists around the pharmacodynamics attributed to ticagrelor and how this may influence its perceived clinical superiority. Additionally, …
-
Downstream Cangrelor versus upstream ticagrelor in patients with St-Segment elevation myocardial infarction
… (ovvero, “downstream”) con il pretrattamento con ticagrelor (ovvero, “upstream”). Metodi: Sono stati inclusi pazienti con STEMI sottoposti a PCI tra ottobre 2019 e giugno 2023. L’endpoint primario era l’insieme degli eventi avversi cardiovascolari maggiori (MACE) durante il ricovero. Gli endpoint …
-
Schnelle und reversible Reduktion der Thrombozytenaktivierung bei Diabetes durch den neuartigen P2Y12-Antagonisten AZD6140 (Ticagrelor)
… des P2Y12-Rezeptor-Antagonisten AZD6140 (Ticagrelor) auf die Plättchenfunktionen diabetischer Ratten. AZD6140 ist ein reversibler, direkter, potenter und oraler Inhibitor des P2Y12-Rezeptors. AZD6140 reduziert als Einzeldosis von 5 mg/ kg Körpergewicht verabreicht die Empfindlichkeit der …
-
Unravelling the antibacterial mechanism of action of ticagrelor and its activity against Staphylococcus aureus infective endocarditis
… garnered interest is the P2Y12 antagonist ticagrelor. Ticagrelor is an antiplatelet drug that was reported to have antibacterial properties against Gram-positive and resistant Gram-positive bacteria including methicillin-resistant Staphylococcus aureus and methicillin-resistant …
-
Τικαγκρελόρη έναντι κλοπιδογρέλης και επαναφόρτισης με τικαγκρελόρη σε ασθενείς με έμφραγμα του μυοκαρδίου με ανάσπαση του ST διαστήματος: μία φαρμακοδυναμική μελέτη
… Inhibition and Patient Outcomes (PLATO) trial, ticagrelor compared with clopidogrel reduced death from vascular causes, myocardial infarction, or stroke in consistence with the overall trial results. Among patients allocated to the ticagrelor in the primary PCI cohort, 40.7% had received pre- …
-
Study of Two Dose Regimens of Ticagrelor Compared with Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention for Stable Coronary Artery Disease (STEEL PCI)
… for the last 2 decades until the adoption of ticagrelor in 2012. Ticagrelor is a potent oral P2Y12 inhibitor that binds reversibly to the receptor and, unlike thienopyridines, has a weak effect on cellular adenosine uptake. Ticagrelor is used first-line, at a dose of 90 mg twice daily, in …
-
Characterization of the antibacterial activity of ticagrelor against resistant Staphylococcus aureus strains: comparison and interaction with daptomycin and vancomycin
… options. Recently, the antiplatelet drug ticagrelor was found to possess bactericidal properties against Gram-positive and resistant Gram-positive bacteria including methicillin-resistant Staphylococcus aureus. The antibacterial properties of ticagrelor were corroborated by several …
-
Μια μονοκεντρική, φάσης ΙΙ, τυφλοποιημένη ως προς τον αξιολογητή, τυχαιοποιημένη, ελεγχόμενη με ενεργό θεραπεία, παράλληλων ομάδων κλινική μελέτη για τη σύγκριση της τικαγκρελόρης έναντι της κλοπιδογρέλης στη μείωση της αορτικής σκληρίας και της ανάκλασης των κυμάτων πίεσης σε ασθενείς με στεφανιαία νόσο: η μελέτη “NOVELTY”
… We compared the acute and midterm effect of ticagrelor versus clopidogrel on aortic stiffness. Methods and Results: We studied 117 patients in a randomized, assessor-blinded, parallel-group trial. The acute effect of ticagrelor was studied in 58 patients randomized (1:1) to receive a loading …
-
Πλειοτροπικές δράσεις αγωνιστών αιμοπεταλιακών υποδοχέων: υποκείμενοι μηχανισμοί και παθοφυσιολογικός ρόλος
Ticagrelor, a potent platelet P2Y12 receptor (P2Y12R), is unique among antiplatelet drugs because it inhibits the P2Y12R in a reversible manner as well as it demonstrates a variety of advantageous pleiotropic effects associated probably with the increased concentration of adenosine. The pleiotropic …
-
Επίδραση της αντιαιμοπεταλιακής αγωγής στη στεφανιαία ροή ασθενών μετά από οξύ στεφανιαίο σύνδρομο
Background— Prasugrel and ticagrelor provide a superior anti-ischemic action than clopidogrel, with some of ticagrelor’s benefits possibly attributed to adenosine-mediated mechanisms. We aimed to compare the effect of maintenance dose of ticagrelor versus prasugrel on coronary blood flow velocity …
-
Εκτίμηση του μυοκαρδιακού εμφράκτου σε τυχαιοποιημένους ασθενείς με οξύ στεφανιαίο σύνδρομο με ανάσπαση του ST διαστήματος, οι οποίοι υποβάλλονται σε θρομβόλυση, υπό κλοπιδογρέλη η τικαγρελόρη
… the faster and stronger antiplatelet action of ticagrelor compared to clopidogrel, as well as its pleiotropic efects, could result in a greater degree of cardioprotection and fnal infarct size (FIS) limitation. The aim of our study was to comparatively evaluate the efect of ticagrelor and …
-
Σύγκριση τικαγκρελόρης με πρασουγρέλη σε οξέα στεφανιαία σύνδρομα: ο ρόλος τους μετά από αγγειοπλαστική και αντίσταση στην κλοπιδογρέλη
… aimed to compare the antiplatelet action of ticagrelor with prasugrel in acute coronary syndrome (ACS) patients with high on-treatment platelet reactivity (HTPR) while on clopidogrel after percutaneous coronary intervention (PCI). Background: Newer P2Y12 inhibitors like prasugrel and …
-
Inhibition of the platelet glycoprotein VI receptor as a potential treatment for acute coronary syndromes
Aspirin and a P2Y\(_{12}\) inhibitor, such as ticagrelor, are routine treatments for myocardial infarction. However, these drugs are not always sufficient for heavy coronary thrombus burden during ST-elevation myocardial infarction (STEMI). More potent antiplatelet drugs (glycoprotein IIb/IIIa …
-
The Effect of Antiplatelet Medications on Innate Immune Activation
… and the novel, more potent P2Y12 inhibitor, ticagrelor, modify these responses in an experimental human model. Approach and Results - We randomized 30 healthy volunteers to ticagrelor (n=10), clopidogrel (n=10) or no antiplatelet medication (controls; n=10). We examined the effect of P2Y12 …
-
Did prasugrel and ticagrelor offer the same benefits in patients with acute coronary syndromes after percutaneous coronary interventions compared to clopidogrel? /
… inhibitor, either clopidogrel, prasugrel or ticagrelor. Despite numerous researches comparing the effectiveness and safety of these three drugs, their relative merits with regards to each other remain to be further elucidated. Objective: the aim of this research is to compare clopidogrel, …
-
The Immobilization of Ticagrelor on Implant Materials and Corrosion and Biofouling Inhibition by Novel Layered Polymer Thin Films for Marine Application
… coating has been prepared by covalent linking of Ticagrelor onto the surface of low carbon stainless steel grade 316L (SS316L) and Cobalt Chromium L605 (CoCr). The surface of stents were functionalized with an amine terminated self-assembled monolayer (SAM). The functionalized surface was modified …
-
Αποτελεσματικότητα της διπλής αντιαιμοπεταλιακής αγωγής με ασπιρίνη και τικαγρελόρη στην πρόληψη εμβολικών εγκεφαλικών επεισοδίων σε ασθενείς που υποβάλλονται σε διακαθετηριακή εμφύτευση βιοπροσθετικής αορτικής βαλβίδας συγκριτικά με ασθενείς που λαμβάνουν ασπιρίνη και κολπιδογρέλη, όπως εκτιμάται από την ανίχνευση παροδικών εμβολικών σημάτων υψηλής έντασης στη ροή των μέσων εγκεφαλικών αρτηριών
… either aspirin and clopidogrel or to aspirin and ticagrelor. High intensity transient signals (HITS) were assessed with transcranial Doppler (TCD). Safety outcomes were recorded according to the VARC-2 definitions. Results: Among 90 patients randomized, 8 had poor TCD signal. In total, 82 patients …
-
Novel P2Y12 Receptor Antagonists - Prasugrel and Ticagrelor. Systematic Review, Indirect Comparison to Clopidogrel in Cardiovascular Disease, Design of a Randomized Controlled Trial
… the new P2Y12 receptor antagonists prasugrel and ticagrelor will increase treatment options. An overview of systematic reviews was performed to summarize available evidence on clopidogrel. Current data on prasugrel and ticagrelor were identified by a systematic review and used for an indirect …
Page 1 of 3